Valuation: Agenus Inc.

Market Cap 126M 111M 102M 95.47M 179M 11.9B 183M 1.23B 474M 5.88B 474M 463M 20.4B P/E 2026 *
3.86x
P/E 2027 * -16.8x
Enterprise Value 126M 111M 102M 95.47M 179M 11.9B 183M 1.23B 474M 5.88B 474M 463M 20.4B EV / Sales 2026 *
0.68x
EV / Sales 2027 * 0.96x
Free-Float
93.3%
Yield 2026 *
-
Yield 2027 * -
1 day+5.21%
1 week+1.00%
Current month-13.43%
1 month-10.88%
3 months-10.62%
6 months-8.46%
Current year-3.50%
1 week 2.85
Extreme 2.85
3.18
1 month 2.85
Extreme 2.85
3.53
Current year 2.71
Extreme 2.71
5.08
1 year 2.71
Extreme 2.71
7.34
3 years 1.38
Extreme 1.38
38.6
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 72 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 72 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap.
06-12Free

Chief Executive Officer

4,925 0.0118%
05-29Free

Chief Executive Officer

4,644 0.0112%
05-15Free

Chief Executive Officer

4,540 0.0118%
Change 5-day change 1-year change 3-year change Capi.($)
+5.21%+1.00%-36.34%-91.14% 126M
+0.62%+7.27%-4.99%+2.64% 46.2B
+2.19%+11.71%+393.31%+580.42% 38.71B
+2.53%+13.93%+21.38%-12.81% 31.9B
+1.65%+3.61%+16.04%+55.62% 31.12B
-4.16%-2.58%+8.94%+25.31% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+130.07% 15.05B
-0.84%+7.78%+13.20%+21.10% 13.74B
+3.63%+9.53%+103.97%+98.73% 13.42B
Average +1.19%+8.32%+65.02%+89.99% 23.02B
Weighted average by Cap. +0.87%+8.70%+88.81%+131.16%

Financials

2026 *2027 *
Net sales 185M 162M 149M 140M 262M 17.42B 268M 1.79B 694M 8.61B 694M 678M 29.86B 131M 115M 106M 99.46M 187M 12.4B 190M 1.28B 494M 6.13B 494M 483M 21.25B
Net income 46M 40.33M 37.18M 34.81M 65.27M 4.34B 66.62M 447M 173M 2.14B 173M 169M 7.44B -9.9M -8.68M -8M -7.49M -14.05M -934M -14.34M -96.17M -37.21M -462M -37.17M -36.36M -1.6B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
26/06/26 $3.030 +5.21% 5,006,329
25/06/26 $2.880 -1.37% 594,632
24/06/26 $2.920 -4.89% 625,201
23/06/26 $3.070 +0.99% 438,569
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.030USD
Average target price
15.50USD
Spread / Average Target
+411.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock